Peripheral blood CD34+ cells differ from bone marrow CD34+ cells in Thy-1 expression and cell cycle status in nonhuman primates mobilized or not mobilized with granulocyte colony-stimulating factor and/or stem cell factor
- PMID: 8608259
Peripheral blood CD34+ cells differ from bone marrow CD34+ cells in Thy-1 expression and cell cycle status in nonhuman primates mobilized or not mobilized with granulocyte colony-stimulating factor and/or stem cell factor
Abstract
Granulocyte colony-stimulating factor (G-CSF) and stem cell factor (SCF) have been shown to stimulate the circulation of hematopoietic progenitor cells in both mice and nonhuman primates. We evaluated the immunophenotype and cell cycle status of CD34+ cells isolated from the bone marrow (BM) and leukapheresis product of cytokine-mobilized nonhuman primates. CD34+ cells were isolated from rhesus macaques that had received no cytokine therapy, 100 micrograms/kg/d G-CSF, 200 micrograms/kg/d SCF, or a combination of both 100 micrograms/kg/d G-CSF and 200 micrograms/kg/d SCF as a subcutaneous injection for 5 days. BM was aspirated before (day 0) and on the last day (day 5) of cytokine administration. On days 4 and 5, peripheral blood (PB) mononuclear cells were collected using a novel method of leukapheresis. Threefold more PB mononuclear cells were collected from animals receiving G-CSF alone or G-CSF and SCF than from animals that had received either SCF alone or no cytokine therapy. CD34+ cells were positively selected using an immunoadsorptive system from the BM, PB, and/or leukapheresis product. Threefold and 10-fold more CD34+ cells were isolated from the leukapheresis product of animals receiving G-CSF or G-CSF and SCF, respectively, than from animals receiving no cytokine therapy or SCF alone. The isolated CD34+ cells were immunophenotyped using CD34-allophycocyanin, CD38-fluorescein isothiocyanate, and Thy-1-phycoerythrin. These cells were later stained with 4', 6-diamidino-2-phenylindole for simultaneous DNA analysis and immunophenotyping. BM-derived CD34+ cells did not differ significantly in cell cycle status and Thy-1 or CD38 phenotype before or after G-CSF and/or SCF administration. Similarly, CD34+ cells isolated from the leukapheresis product did not differ significantly in immunophenotype or cell cycle status before or after G-CSF and/or SCF administration. However, there were consistent differences in both immunophenotype and cell cycle status between BM- and PB-derived CD34+ cells. CD34+ cells isolated from the PB consistently had a smaller percentage of cells in the S+G2/M phase of the cell cycle and had a higher percentage of cells expressing Thy-1 than did CD34+ cells isolated from the BM. A greater proportion of PB-derived CD34+ cells were in the S+G2/M phase of the cell cycle after culture in media supplemented with interleukin-6 and SCF, However, culturing decreased the proportion of CD34+ cells expressing Thy-1.
Similar articles
-
Improved retroviral gene transfer into murine and Rhesus peripheral blood or bone marrow repopulating cells primed in vivo with stem cell factor and granulocyte colony-stimulating factor.Proc Natl Acad Sci U S A. 1996 Oct 15;93(21):11871-6. doi: 10.1073/pnas.93.21.11871. Proc Natl Acad Sci U S A. 1996. PMID: 8876230 Free PMC article.
-
A comparative study of the phenotype and proliferative capacity of peripheral blood (PB) CD34+ cells mobilized by four different protocols and those of steady-phase PB and bone marrow CD34+ cells.Blood. 1994 Nov 1;84(9):2930-9. Blood. 1994. PMID: 7524760
-
Phenotypic and functional characterization of long-term culture-initiating cells present in peripheral blood progenitor collections of normal donors treated with granulocyte colony-stimulating factor.Blood. 1996 Sep 15;88(6):2033-42. Blood. 1996. PMID: 8822922
-
The role of granulocyte colony-stimulating factor in mobilization and transplantation of peripheral blood progenitor and stem cells.Cytokines Mol Ther. 1995 Dec;1(4):249-70. Cytokines Mol Ther. 1995. PMID: 9384679 Review.
-
The role of stem cell factor and granulocyte-colony stimulating factor in treatment of stroke.Recent Pat CNS Drug Discov. 2013 Apr;8(1):2-12. doi: 10.2174/1574889811308010002. Recent Pat CNS Drug Discov. 2013. PMID: 23173646 Free PMC article. Review.
Cited by
-
Efficient manufacturing and engraftment of CCR5 gene-edited HSPCs following busulfan conditioning in nonhuman primates.Mol Ther Methods Clin Dev. 2023 Jul 18;30:276-287. doi: 10.1016/j.omtm.2023.07.006. eCollection 2023 Sep 14. Mol Ther Methods Clin Dev. 2023. PMID: 37575091 Free PMC article.
-
Cyclophosphamide/granulocyte colony-stimulating factor induces hematopoietic stem cells to proliferate prior to mobilization.Proc Natl Acad Sci U S A. 1997 Mar 4;94(5):1908-13. doi: 10.1073/pnas.94.5.1908. Proc Natl Acad Sci U S A. 1997. PMID: 9050878 Free PMC article.
-
Hematopoietic reconstitution dynamics of mobilized- and bone marrow-derived human hematopoietic stem cells after gene therapy.Nat Commun. 2023 May 27;14(1):3068. doi: 10.1038/s41467-023-38448-y. Nat Commun. 2023. PMID: 37244942 Free PMC article. Clinical Trial.
-
Significant mobilization of both conventional and regulatory T cells with AMD3100.Blood. 2011 Dec 15;118(25):6580-90. doi: 10.1182/blood-2011-06-359331. Epub 2011 Oct 11. Blood. 2011. PMID: 21989987 Free PMC article.
-
AMD3100 mobilizes hematopoietic stem cells with long-term repopulating capacity in nonhuman primates.Blood. 2006 May 1;107(9):3772-8. doi: 10.1182/blood-2005-09-3592. Epub 2006 Jan 26. Blood. 2006. PMID: 16439684 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous